Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.
Ceftobiprole medocaril is a newly approved drug in Europe for the treatment of hospital-acquired pneumonia (HAP) (excluding patients with ventilator-associated pneumonia but including ventilated HAP patients) and community-acquired pneumonia in adults. The aim of this study was to evaluate the in vitro antimicrobial activity of ceftobiprole against prevalent Gram-positive and -negative pathogens isolated in Europe, Turkey, and Israel during 2005 through 2010. A total of 60,084 consecutive, nonduplicate isolates from a wide variety of infections were collected from 33 medical centers. Species identification was confirmed, and all isolates were susceptibility tested using reference broth microdilution methods. Ceftobiprole had high activity against methicillin-susceptible Staphylococcus aureus (MSSA) (100.0% susceptible), methicillin-susceptible coagulase-negative staphylococci (CoNS), beta-hemolytic streptococci, and Streptococcus pneumoniae (99.3% susceptible), with MIC90 values of 0.25, 0.12, ≤ 0.06, and 0.5 μg/ml, respectively. Ceftobiprole was active against methicillin-resistant S. aureus (MRSA) (98.3% susceptible) and methicillin-resistant CoNS, having a MIC90 of 2 μg/ml. Ceftobiprole was active against Enterococcus faecalis (MIC50/90, 0.5/4 μg/ml) but not against most Enterococcus faecium isolates. Ceftobiprole was very potent against the majority of Enterobacteriaceae (87.3% susceptible), with >80% inhibited at ≤ 0.12 μg/ml. The potency of ceftobiprole against Pseudomonas aeruginosa (MIC50/90, 2/>8 μg/ml; 64.6% at MIC values of ≤ 4 μg/ml) was similar to that of ceftazidime (MIC50/90, 2/>16 μg/ml; 75.4% susceptible), but limited activity was observed against Acinetobacter spp. and Stenotrophomonas maltophilia. High activity was also observed against all Haemophilus influenzae (MIC90, ≤ 0.06 μg/ml) and Moraxella catarrhalis (MIC50/90, ≤ 0.06/0.25 μg/ml) isolates. Ceftobiprole demonstrated a wide spectrum of antimicrobial activity against this very large longitudinal sample of contemporary pathogens.
JMI Laboratories, North Liberty, Iowa, USA Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada david-farrell@jmilabs.com.
David J
DJ
Farrell
JMI Laboratories, North Liberty, Iowa, USA.
Robert K
RK
Flamm
JMI Laboratories, North Liberty, Iowa, USA Division of Infectious Diseases, Federal University of São Paulo, São Paulo, Brazil.
Helio S
HS
Sader
JMI Laboratories, North Liberty, Iowa, USA Tufts University School of Medicine, Boston, Massachusetts, USA.
Ronald N
RN
Jones
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000382:microbiology*; D002511:Cephalosporins / Q000494:pharmacology*; D005060:Europe; D006801:Humans; D007557:Israel; D008826:Microbial Sensitivity Tests / Q000592:standards; D062486:Public Health Surveillance; D012015:Reference Standards; D014421:Turkey
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C443755:ceftobiprole